PLM-101 is an orally available anticancer agent targeting FLT3 and RET with inhibitory activity against acute myeloid leukemia cells. PLM-101 inhibits RET, thereby inducing autophagic degradation of FLT3, and it inhibits the PI3K and Ras/ERK pathways, resulting in anti-leukemia activity. PLM-101 has anti-tumor efficacy in a mouse MV4-11 flank xenograft model (dose: 3, 10 mg/kg, po) and an allogeneic xenograft mouse model (dose: 40 mg/kg, po)[1].
Molecular Weight:
407.44
Formula:
C22H22FN5O2
Target:
FLT3,RET
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
